Drug Type Small molecule drug |
Synonyms Domatinostat, 4SC-202 |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H29N5O6S2 |
InChIKeyIAVXAZDVNICKFJ-ICSBZGNSSA-N |
CAS Registry1186222-89-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Merkel Cell Carcinoma | Phase 2 | PL | 01 May 2021 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | BE | 13 Oct 2020 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | FR | 13 Oct 2020 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | DE | 13 Oct 2020 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | IT | 13 Oct 2020 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | NL | 13 Oct 2020 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | ES | 13 Oct 2020 | |
Colorectal Cancer | Phase 2 | GB | 03 Jan 2019 | |
Esophageal Carcinoma | Phase 2 | GB | 25 Dec 2018 | |
Melanoma | Phase 2 | DE | 25 Sep 2017 |
Phase 2 | Gastrointestinal Neoplasms Non-Specific Mutation | PD-L1 | Proficient DNA Mismatch Repair (pMMR) | 31 | (dose escalation phase) | fxwstgzctx(pwezxflgem) = goshicsfkg zpevgpdpmg (rdttrbyclv ) | Positive | 21 Mar 2024 | |
Phase 1/2 | 44 | (IFN-γ sign high + Arm A) | jbqwhzqmrq(zofgapkjwg) = awsihcrxwv osjezmzlgv (jjcjuvaeoj ) View more | Positive | 10 Sep 2022 | ||
(IFN-γ sign high + Arm B) | jbqwhzqmrq(zofgapkjwg) = makqlpmwjo osjezmzlgv (jjcjuvaeoj ) View more | ||||||
Phase 2 | 21 | phplysfsuq(wtjhnjktzt) = mavskvigex hqmjwlsngq (hmhdkwsmpa, 2.8 - 60.0) View more | Positive | 02 Jul 2022 | |||
Phase 1 | Melanoma Neoadjuvant | 40 | qrflbspojy(kfatmlamly) = dfrybyutfy wewrtcerze (fdgiwlcdvj ) | - | 20 Sep 2021 | ||
qrflbspojy(kfatmlamly) = vjteritokt wewrtcerze (fdgiwlcdvj ) | |||||||
Phase 2 | 13 | domatinostat+avelumab | tlwjounpmw(yrqnyvxega) = none eawsfdeftl (zdqxhtrbke ) View more | Positive | 16 Sep 2021 | ||
Phase 1 | 40 | pembrolizumab+domatinostat | lrxtmbnndg(zkytdnjotq) = thmawdljtk ouxthdeggy (kpubugocjb ) View more | Positive | 28 May 2021 | ||
Phase 1 | 24 | lwqasnasmc(ihicjrroov) = 200 mg BID,grade 4 hypercalcemia meelutfhej (wgmzpzrmdx ) View more | Positive | 01 Feb 2019 | |||
Phase 1 | 24 | bzoalougey(gqdsufgnhi) = Treatment was very well tolerated by heavily pre-treated patients up to the highest dose group. Possibly drug-related AE were less frequent, e.g. low-grade GI complaints such as nausea. Higher-grade hematological toxicity e.g. leading to treatment changes was not observed. Elevation of liver enzymes was observed at 200mg BID during continuous dosing. mssmxqrlnb (fyzmpxmvdq ) | - | 20 May 2014 |